GlassScriptPhysician profile
Lacey Ante
NPI 1720681091
$4,173.34
in general payments reported to CMS, 2019-2025
27 companies · $41.79 in 2025
The $41.79 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $2,737 · 2023: $774 · 2024: $81.72 · 2025: $41.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,413.39 | 2021-2024 | Urolift |
| Medtronic, INC. | $405.70 | 2022-2023 | Interstim |
| Sumitomo Pharma America, INC. | $144.07 | 2023 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $123.39 | 2022 | |
| Procept Biorobotics Corporation | $108.02 | 2022 | |
| Abbvie INC. | $106.67 | 2021-2025 | |
| Antares Pharma, INC. | $71.49 | 2022 | |
| Urovant Sciences INC | $70.15 | 2022 | |
| Convatec INC. | $68.59 | 2022-2023 | |
| Coloplast Corp | $66.74 | 2022 | |
| Endo Pharmaceuticals INC. | $65.44 | 2021-2023 | Aveed, Xiaflex |
| Astrazeneca Pharmaceuticals LP | $62.68 | 2023 | Lynparza |
| Janssen Biotech, INC. | $56.64 | 2022 | |
| Astellas Pharma US INC | $55.01 | 2022-2023 | Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2022 | |
| Boston Scientific Corporation | $35.22 | 2023-2025 | General - Kidney Stone Disease |
| Merck Sharp & Dohme LLC | $29.94 | 2023 | Keytruda, Lynparza |
| Mission Pharmacal Company | $29.28 | 2022 | |
| Ambu INC. | $28.95 | 2021 | |
| Myovant Sciences INC. | $28.34 | 2022 | |
| Lundbeck LLC | $24.12 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.39 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.89 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.92 | 2023 | Natesto |
| Intuitive Surgical, INC. | $16.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Ante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.